At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 435 enrolled
Drug / intervention
insulin degludec +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pan Asian Trial Comparing Efficacy and Safety of Insulin NN1250 and Insulin Glargine as Add on to OAD(s) in Subjects With Type 2 Diabetes (BEGIN™: ONCE ASIA)
In Brief
A Phase 3 clinical trial evaluating insulin degludec and insulin glargine for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 435 participants across 53 sites in 6 countries.
Detailed Summary
This trial is conducted in Asia and Japan. The aim of this trial is to compare insulin degludec (NN1250) with insulin glargine both combined with oral antidiabetic drugs (OADs) in subjects with type 2 diabetes never treated with insulin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesHong Kong, Japan, Malaysia, South Korea, Taiwan, Thailand
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2010
Enrollment StartFeb 2010
Primary CompletionDec 2010
TodayJul 2026
First PostedFeb 1, 2010
Enrollment StartFeb 1, 2010
Primary CompletionDec 16, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 16.4 years ago
Interventions
insulin degludecdrug
Insulin degludec injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
insulin glarginedrug
Insulin glargine injected subcutaneously (under the skin) once daily. The doses will be individually adjusted